B03 Identification and characterisation of overexpression suppressors of mutant huntingtin toxicity

Mason, R; Fearnley, N; Bishop, C; Möller, T; Giorgini, F
September 2010
Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA11
Academic Journal
Several genetic and chemical modifier screens have been performed in yeast models of Huntington's disease (HD) to identify deletion suppressors, deletion enhancers and chemical modifiers of mutant huntingtin (htt) toxicity. These screens have provided valuable insights into the cellular processes altered in HD and led to the identification of several promising therapeutic compounds, including inhibitors of kynurenine-3-monooxygenase (KMO). To complement these screens we have performed an overexpression suppressor screen in a yeast model of HD. Using a yeast model of HD we have screened murine cDNA libraries and identified 84 unique murine cDNAs capable of suppressing mutant htt toxicity when overexpressed in yeast. The suppressors encode proteins involved in a range of cellular processes altered in HD, including apoptosis, response to oxidative stress, protein folding, vesicle trafficking, autophagy and mitochondrial function. Several suppressors have also previously been implicated in neurodegeneration. To validate the suppressors we have stably overexpressed cDNAs selected from several functional groups in an inducible PC12 model of HD. The eight cDNA suppressors tested all significantly reduce the activation of caspase 3/7 observed on induction of mutant htt expression in this cell model. Three of these suppressors also improve several metrics in a model of HD. In conclusion, we have identified a large number of suppressors of mutant htt toxicity and validated a number of these using a range of models. The validation of a subset of these suppressors in both mammalian and models of HD suggests that the majority of the 84 cDNAs identified in the yeast screen will retest in higher organisms. This screen has identified several cellular pathways and specific proteins for therapeutic targeting and we are currently in the process of testing compounds that mimic overexpression of selected suppressors.


Related Articles

  • B02 Validation of suppressors of mutant huntingtin toxicity in a fly model of Huntington's disease. Casu, M; Campesan, S; Clapp, J; Kyriacou, C P; Giorgini, F // Journal of Neurology, Neurosurgery & Psychiatry;Sep2010 Supp, Vol. 81, pA11 

    Studies using yeast models of Huntington's disease (HD) have provided insight into mechanisms underlying mutant huntingtin (htt) toxicity and have also identified several promising therapeutic targets for this disorder. Of particular note, we identified the candidate drug target kynurenine...

  • Neurodegenerative disease: Hunting out the NUB1 of the matter. Flight, Monica Hoyos // Nature Reviews Neuroscience;May2013, Vol. 14 Issue 5, p308 

    The article discusses research related to the Huntington's disease. It references the study "Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance," by B. Lu and colleagues in the March 24, 2013 issue of "Nature Neuroscience." It mentions that...

  • A Genome-Scale RNA--Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington's Disease. Miller, John P.; Yates, Bridget E.; Al-Ramahi, Ismael; Berman, Ari E.; Sanhueza, Mario; Kim, Eugene; de Haro, Maria; DeGiacomo, Francesco; Torcassi, Cameron; Holcomb, Jennifer; Gafni, Juliette; Mooney, Sean D.; Botas, Juan; Ellerby, Lisa M.; Hughes, Robert E. // PLoS Genetics;Nov2012, Vol. 8 Issue 11, Special section p1 

    A genome-scale RNAi screen was performed in a mammalian cell-based assay to identify modifiers of mutant huntingtin toxicity. Ontology analysis of suppressor data identified processes previously implicated in Huntington's disease, including proteolysis, glutamate excitotoxicity, and...

  • Huntingtin Aggregation Kinetics and Their Pathological Role in a Drosophila Huntington's Disease Model. Weiss, Kurt R.; Kimura, Yoko; Wyan-Ching Mimi Lee; Littleton, J. Troy // Genetics;Feb2012, Vol. 190 Issue 2, p581 

    Huntington's disease is a neurodegenerative disorder resulting from expansion of a polyglutamine tract in the Huntingtin protein. Mutant Huntingtin forms intracellular aggregates within neurons, although it is unclear whether aggregates or more soluble forms of the protein represent the...

  • Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Mason, Robert P; Casu, Massimiliano; Butler, Nicola; Breda, Carlo; Campesan, Susanna; Clapp, Jannine; Green, Edward W; Dhulkhed, Devyani; Kyriacou, Charalambos P; Giorgini, Flaviano // Nature Genetics;Oct2013, Vol. 45 Issue 10, p1249 

    Huntington's disease is a fatal neurodegenerative disorder caused by a CAG repeat expansion encoding a polyglutamine tract in the huntingtin (Htt) protein. Here we report a genome-wide overexpression suppressor screen in which we identified 317 ORFs that ameliorate the toxicity of a mutant Htt...

  • Tracking down huntingtin. López, Juan Carlos // Nature Medicine;Aug2004, Vol. 10 Issue 8, p776 

    Reports on the results of the study dissecting the molecular basis of Huntington's chorea in the U.S. Gene mutations encoding the protein huntingtin; Examination whether the disease is caused by the loss of huntingtin; Association of the pathogenic mechanism with the toxicity of the mutant protein.

  • Human genetics: Drawn into bad company. Skipper, Magdalena // Nature Reviews Genetics;Aug2004, Vol. 5 Issue 8, p563 

    Examines the role of polyglutamine repeat expansions in several human disorders, with an emphasis on Huntington disease. Inability of transcription factors to bind their DNA targets with mutant huntingtin; Possible effect of expanded tracts of polyglutamine on disease; Toxicity of polyglutamine...

  • Non-coding RNAs in polyglutamine disorders: friend or foe? Sengupta, Sonali; Ganesh, Subramaniam // Journal of Biosciences;Jun2008, Vol. 33 Issue 2, p303 

    The article focuses on the role of non-coding ribonucleic acids (RNA) in polyglutamine (polyQ) disorders. It states that several research showed that overexpression of RNA was found to enhance polyQ protein-induced toxicity in fly models expressing the expanded polyQ or the mutant huntingtin...

  • Palmitoylation of huntingtin by HIP14is essential for its trafficking and function. Yanai, Anat; Kun Huang; Rujun Kang; Singaraja, Roshni R.; Arstikaitis, Pamela; Lu Gan; Orban, Paul C.; Mullard, Asher; Cowan, Catherine M.; Raymond, Lynn A.; Drisdel, Renaldo C.; Green, William N.; Ravikumar, Brinda; Rubinsztein, David C.; El-Husseini, Alaa; Hayden, Michael R. // Nature Neuroscience;Jun2006, Vol. 9 Issue 6, p824 

    Post-translational modification by the lipid palmitate is crucial for the correct targeting and function of many proteins. Here we show that huntingtin (htt) is normally palmitoylated at cysteine 214, which is essential for its trafficking and function. The palmitoylation and distribution of htt...


Read the Article


Sign out of this library

Other Topics